Avicanna Inc (TSX:AVCN, OTCQX:AVCNF) has announced that Chandra Panchal, PhD is retiring as chairman of its board of directors and that it will initiate a search for a new director.
“During his tenure with Avicanna, Dr Panchal witnessed our evolution from a pre-commercial R&D-stage company into an international biopharmaceutical company and assisted management with various external challenges and internal growing pains along the way,” Avicanna CEO Aras Azadian commented in a statement.
"With the company recently closing a transformational acquisition, launching MyMedi.ca, and reporting record revenues, I am proud of the company’s management and employees who have developed Avicanna from a fledgling start-up to an international player in a short period of time," Panchal added.
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. The company has an established scientific platform, including R&D and clinical development that has led to the commercialization of more than 30 products across various market segments.
Contact the author at stephen.gunnion@proactiveinvestors.com